Table 3.
Hazard ratios for discontinuation of non-ergoline DA treatment in overall population
| Demographic/clinical characteristics | Crude HR, n = 90 |
|---|---|
| Gender | |
| Male | Reference |
| Female | 0.75 (0.43–1.31) |
| Age | |
| <65 years | Reference |
| ≥65 years | 1.04 (0.57–1.91) |
| Duration of PD | |
| <5 years | Reference |
| ≥5 years | 0.81 (0.46–1.41) |
| Treatment | |
| Ropinirole | Reference |
| Pramipexole | 1.15 (0.66–2.02) |
| Concomitant use of other antiparkinsonian drugs at index date (%)a | |
| Amantadine | 0.76 (0.36–1.62) |
| Selegeline | 0.97 (0.35–2.71) |
| Apomorphineb | 6.26 (1.85–21.2) |
| Other dopamine agonist | 0.05 (0–702) |
| Levodopa | 1.26 (0.70–2.28) |
| Daily levodopa dosage at index date | |
| <500 mg | Reference |
| ≥500 mg–1000 mgb | 2.31 (1.08–4.93) |
| ≥1000 mg | 1.59 (0.47–5.37) |
| Concomitant use of other medication at index date (%)a | |
| Antipsychotics | 0.62 (0.25–1.57) |
| Antidepressants | 0.68 (0.21–2.18) |
| Daily dopamine agonist dosage c | |
| <0.75 DDD | Reference |
| ≥0.75–1.50 DDDb | 0.39 (0.20–0.75) |
| ≥1.50 DDDb | 0.39 (0.17–0.88) |
Values are given as the hazard ratio (HR), with the 95% confidence interval (CI) in parenthesis
a Presence vs. absence (Reference)
bFactors associated with non-ergoline DA discontinuation
cMean of entire follow-up period: 1 DDD ropinirole = 6.0 mg; 1 DDD pramipexole = 2.5 mg (as established by the World Health Organization Collaborating Centre for Drug Statistics Methodology)